Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer

by Cato, Laura, Neeb, Antje, Sharp, Adam, Buzón, Victor, Ficarro, Scott B, Yang, Linxiao, Muhle-Goll, Claudia, Kuznik, Nane C, Riisnaes, Ruth, Nava Rodrigues, Daniel, Armant, Olivier, Gourain, Victor, Adelmant, Guillaume, Ntim, Emmanuel A, Westerling, Thomas, Dolling, David, Rescigno, Pasquale, Figueiredo, Ines, Fauser, Friedrich, Wu, Jennifer, Rottenberg, Jaice T, Shatkina, Liubov, Ester, Claudia, Luy, Burkhard, Puchta, Holger, Troppmair, Jakob, Jung, Nicole, Bräse, Stefan, Strähle, Uwe, Marto, Jarrod A, Nienhaus, Gerd Ulrich, Al-Lazikani, Bissan, Salvatella, Xavier, de Bono, Johann S, Cato, Andrew CB, Brown, Myles
Published 2017

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.

by Yap, Timothy A, Kristeleit, Rebecca, Michalarea, Vasiliki, Pettitt, Stephen J, Lim, Joline SJ, Carreira, Suzanne, Roda, Desamparados, Miller, Rowan, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rodrigues, Daniel Nava, Ward, Sarah, Matthews, Ruth, Parmar, Mona, Turner, Alison, Tunariu, Nina, Chopra, Neha, Gevensleben, Heidrun, Turner, Nicholas C, Ruddle, Ruth, Raynaud, Florence I, Decordova, Shaun, Swales, Karen E, Finneran, Laura, Hall, Emma, Rugman, Paul, Lindemann, Justin PO, Foxley, Andrew, Lord, Christopher J, Banerji, Udai, Plummer, Ruth, Basu, Bristi, Lopez, Juanita S, Drew, Yvette, de Bono, Johann S
Published 2020

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

by Yap, Timothy A, Yan, Li, Patnaik, Amita, Tunariu, Nina, Biondo, Andrea, Fearen, Ivy, Papadopoulos, Kyriakos P, Olmos, David, Baird, Richard, Delgado, Liliana, Tetteh, Ernestina, Beckman, Robert A, Lupinacci, Lisa, Riisnaes, Ruth, Decordova, Shaun, Heaton, Simon P, Swales, Karen, deSouza, Nandita M, Leach, Martin O, Garrett, Michelle D, Sullivan, Daniel M, de Bono, Johann S, Tolcher, Anthony W
Published 2015

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose...

by Guo, Christina, Chénard-Poirier, Maxime, Roda, Desamparados, de Miguel, Maria, Harris, Samuel J, Candilejo, Irene Moreno, Sriskandarajah, Priya, Xu, Wen, Scaranti, Mariana, Constantinidou, Anastasia, King, Jenny, Parmar, Mona, Turner, Alison J, Carreira, Suzanne, Riisnaes, Ruth, Finneran, Laura, Hall, Emma, Ishikawa, Yuji, Nakai, Kiyohiko, Tunariu, Nina, Basu, Bristi, Kaiser, Martin, Lopez, Juanita Suzanne, Minchom, Anna, de Bono, Johann S, Banerji, Udai
Published 2020